Reviva Pharmaceuticals Announces 1-for-20 Reverse Stock Split Effective March 9, 2026
In a regulatory filing, Reviva Pharmaceuticals announced that on March 4, the company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which will effect, at 12:01 a.m. Eastern Time on March 9, 2026, a one-for-twenty reverse stock split of the company's issued and outstanding shares of common stock, par value $0.0001 per share. The trading symbol for the Common Stock will remain "RVPH". The company anticipates that the Common Stock will begin trading on a Reverse Stock Split-adjusted basis when the market opens on March 9, 2026. As a result of the Reverse Stock Split, every twenty shares of Common Stock issued and outstanding will be converted into one share of Common Stock. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the company's equity, except to the extent that the Reverse Stock Split would result in some stockholders owning a fractional share. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.
